Arthneeti
Latest: Shilpa Medicare Q1 FY27 (Apr–Jun 2026) results →This page is Q3 FY26 (Oct–Dec 2025).All Q3 FY26 results →
SM

Shilpa Medicare

Q3 FY26Pharmaceuticals & Biotechnology

Shilpa Medicare Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Price₹815
Market cap₹15.9K Cr
P/E56.1
Updated23 Aug 2026
Read4 min read

The short version

FY '27 expected to have strong growth momentum, building on Q3's solid 30% growth. Highest ever quarterly revenue of INR411 crores in Q3 FY '26, growing 28% YoY; 9 months revenue at INR1,110 crores, up 14%.

From Shilpa Medicare's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • FY '27 expected to have strong growth momentum, building on Q3's solid 30% growth.
  • Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income.
  • Launches like NorUDCA and transdermal Rotigotine to boost revenues.
  • Biologics and Formulation segments anticipated to drive higher growth; API segment to grow steadily.
  • Increased utilization and new oral solid line at formulation plant to support revenue ramp-up.
  • Oncology business expected to grow with resolved product validations and increased capacity.
  • CDMO peptide facility launching with ~INR40 crore capex, expecting inquiries and scale-up.
  • Licensing income stable at ~INR150 crores annually, with quarter-to-quarter variations normal.

2 more points from Shilpa Medicare's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Shilpa Medicare said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • New peptide capacity planned with a capex of around INR 40 crores to cater to growing GLP-1 peptide demand and CDMO opportunities (Page 13).
  • Investment in a new oral solid formulation line recently commissioned to support upcoming launches and generate additional revenues in FY '27 (Page 15).
  • Significant past capex completed; current focus is on execution, scaling, and maximizing ROCE from existing investments (Page 6).
  • Capex of about INR 87 crores incurred during Q3 FY '26, with expectation to mainly fund capex through internal accruals (Page 6).

2 more points from Shilpa Medicare's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Shilpa Medicare said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • NorUDCA launch has been very successful, exceeding expectations with a strong order book as of Q3 FY26.
  • Good traction in NorUDCA is noted with an expanding order book from the three marketing partners.
  • Formulation segment shows stable base revenue, with Europe at ~INR73 crores indicating a steady order flow.

2 more points from Shilpa Medicare's call on order book

Create a free account to keep reading this call

Shilpa Medicare — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹437 Cr, net profit ₹108 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Shilpa Medicare Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Guj. Themis Bio. (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Shilpa Medicare and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Shilpa Medicare Q3 FY26 results?

FY '27 expected to have strong growth momentum, building on Q3's solid 30% growth. Highest ever quarterly revenue of INR411 crores in Q3 FY '26, growing 28% YoY; 9 months revenue at INR1,110 crores, up 14%.

What is Shilpa Medicare share price analysis?

Shilpa Medicare currently shows a neutral. The stock trades at a P/E of 56.0 with a market cap of ₹15,939 Cr. Investors should review the full earnings analysis for detailed insights.

Is Shilpa Medicare planning capital expenditure?

New peptide capacity planned with a capex of around INR 40 crores to cater to growing GLP-1 peptide demand and CDMO opportunities (Page 13).

Keep Shilpa Medicare on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.